Compare Sanofi SA (SNY) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Simon Property Group Inc — how do they compare? Sanofi SA trades at $40.14 (market cap $95.18B), while Simon Property Group Inc trades at $200.04 (market cap $64.59B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Simon Property Group Inc for 99 Days on average.
| SNY | SPG | |
|---|---|---|
Market Cap | $95.18B | $64.59B |
Volume | 2,995,646 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $52.34 | $236.70 |
52-Week Low | $39.51 | $173.35 |
Typical Hold Time | 94 Days | 99 Days |
Enterprise Value | $114.48B | $93.03B |
Dividend Yield | 6.01% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
SPG trades at $199.96, up 1.2% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with revenue of $6.36B and net income of $4.63B, though Q2 2026 earnings missed expectations. Analyst consensus is a $222.90 price target with 42% buy ratings. Recent news highlights strong leasing demand and a new media network launch, while rising bond yields pose a sector headwind.
SPG offers value with a P/E of 14.09 and robust profitability margins, but faces risks from high leverage with $24.21B in long-term debt and sensitivity to interest rates. The stock's current price below the consensus target suggests potential upside if operational strength continues, though investors should weigh debt maturities and economic cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
